Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Status:
Enrolling by invitation
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy,
safety, and tolerability of zilucoplan in subjects with gMG who have previously participated
in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.